Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement. (10th September 2020)

• Record Type: Journal Article
• Authors: Lenihan, Daniel; Carver, Joseph; Porter, Charles; Liu, Jennifer E.; Dent, Susan; Thavendiranathan, Paaladinesh; Mitchell, Joshua D.; Nohria, Anju; Fradley, Michael G.; Pusic, Iskra; Stockerl‐Goldstein, Keith; Blaes, Anne; Lyon, Alexander R.; Ganatra, Sarju; López‐Fernández, Teresa; O'Quinn, Rupal; Minotti, Giorgio; Szmit, Sebastian; Cardinale, Daniela; Alvarez‐Cardona, Jose; Curigliano, Giuseppe; Neilan, Tomas G.; Herrmann, Joerg
• Is Part Of: CA. Volume 70:Number 6(2020)
• Page Start: 480
• Page End: 504
• Publication Date: 2020-09-10
• Subjects: best practice -- cancer -- cardiac safety -- cardio‐oncology -- coronavirus disease 2019 (COVID‐19) -- pandemic -- recommendations -- virus; Cancer -- Periodicals; Neoplasms -- Periodicals; Neoplasms; 616.99405
• DOI: 10.3322/caac.21635
• Languages: English
• ISSNs: 0007-9235

Abstract

Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID‐19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID‐19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio‐oncology and outlines key modifications in the approach to this ever‐increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS–CoV‐2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.